 |
 |
 |
 |
 |
 |
|
||||||||||||||
SELECT PUBLICATIONS
Coombes RC et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract
Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97(17):1262-71. Abstract
Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract
Howell A et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract
Jakesz R et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366(9484):455-62. Abstract
Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34. Abstract
Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26. Abstract
Piccart-Gebhart MJ et al. Trastuzumab after adjuvant chemotherapy in HER 2-positive breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER 2 positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract
Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide
followed by docetaxel (AC 
T) with doxorubicin and cyclophosphamide
followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and
trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study.
Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 1.
Thürlimann B et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353(26):2747-57. Abstract
Winer EP et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004. J Clin Oncol 2005;23(3):619-29. Abstract
| Table of Contents | Top of Page |
